Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT05967949
Recruiting Observational

A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.

NCT05967949 · tracked via the Priya Life Science China tracker
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Phase
Observational
Started
2023-04-01
Last updated
2023-08-01

Condition(s) studied

PTCL

Investigational drug(s) / intervention(s)

chidamide →

chidamide: This subset of patients received chidamide as first-line maintenance therapy.

Study summary

The efficacy and safety of chidamide in first-line maintenance therapy for PTCL will be assessed through a retrospective case analysis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * (1) Age: 18 years and older; (2) Gender: Male/Female; (3) Diagnosed with PTCL; (4) Received chidamide as maintenance therapy after first-line treatment. Exclusion Criteria: * (1) Patients with other types of lymphomas; (2) Pregnant women.

Primary outcome measure(s)

  • PFS — 2 years
    progression free survival

Trial sites (1)

FacilityCityRegionStatus
Hematological Department, People's Hospital of Jiangsu Province Nanjing Jiangsu Recruiting

More The First Affiliated Hospital with Nanjing Medical University trials in China

Protection of Cardiac Function With Left Bundle Branch Pacing in Patients With Atrioventricular Block Active, not recruiting
Predicting Ventilator-associated Lower Respiratory Tract Infection Outcomes Using Sequenced-based Early Microbiological Response Recruiting
A Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT) Starting soon
Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma Starting soon
Study in Human iPSCs-derived RPE Cells Transplantation for Advanced (Late-stage) AMD Recruiting

Other trials for the same condition

A Phase I/II Study of FG-M131 in TRBC1+ Relapsed/Refractory Peripheral T-Cell Lymphoma Starting soon
SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma Starting soon
Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL Recruiting
TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05967949 on ClinicalTrials.gov ↗ ← All trials in China